ARCT ▼ -1.5% - Arcturus Therapeutics Holdings Inc. $ARCT Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform Arcturus Therapeutics fell 1.5% today as the company announced plans to present Phase 2 clinical data for its OTC deficiency candidate and provide updates on its mRNA liver therapeutics platform. The decline suggests investors may have tempered enthusiasm ahead of the data presentation, or are awaiting concrete efficacy and safety details before reassessing the stock's prospects. 18-SEP-2026 09:00 AM ET